The MOU is an early-stage exploratory agreement with no binding commitments. Watch for regulatory/ethics committee approvals and enrollment initiation to confirm the trial materializes. No immediate revenue or revenue catalyst.
Price Chart
Executive Summary
Alpha Tau signed a non-binding MOU with Samsung Medical Center (SMC) to explore a potential clinical trial of Alpha DaRT for pancreatic cancer in South Korea. The trial is subject to regulatory and ethics approvals and represents the company's first planned study in Korea, expanding its pancreatic cancer program to six countries. No financial terms, milestones, or committed funding were disclosed.
Key Facts
- MOU signed with Samsung Medical Center (SMC), ranked #5 globally and #1 in Korea in oncology (Newsweek 2027).
- Potential clinical trial of Alpha DaRT for pancreatic cancer patients in South Korea — first such trial in Korea.
- Any trial is subject to regulatory and ethics committee approvals.
- Pancreatic cancer is Korea's 4th leading cause of cancer death; 5-year survival rate is 17.0%.
- SMC performed >4,000 pancreatectomies for pancreatic cancer between 2008 and 2025.
- No financial terms, milestones, or funding commitments disclosed in the MOU.
- Alpha DaRT has marketing approval only in Japan for head and neck cancer; not approved elsewhere.
Financial Impact
No financial terms, milestones, or committed funding disclosed in the MOU.
Risk Factors
- Trial may not receive regulatory or ethics committee approvals.
- MOU is non-binding; SMC may not proceed with the trial.
- Alpha DaRT has limited commercial approvals; pancreatic cancer program is still preclinical/early-stage for this indication.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111493 |
| Document: ea0309330-6k_alpha.htm | 0001213900-26-111493 |
| Document: 0001213900-26-111493-index-headers.html | 0001213900-26-111493 |
| Document: 0001213900-26-111493-index.html | 0001213900-26-111493 |
| Document: 0001213900-26-111493.txt | 0001213900-26-111493 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 22, 2026 5d ago | Press Release | $12.90 | awaiting T+60 | awaiting T+60 | $13.51 (+4.73%) |
Oct 19, 2026 8d ago | 6-K | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Oct 19, 2026 8d ago | Press Release | $12.62 | awaiting T+60 | awaiting T+60 | $13.51 (+7.05%) |
Aug 31, 2026 8w ago | 6-K | $14.11 | awaiting T+60 | awaiting T+60 | $13.51 (−4.25%) |
Aug 10, 2026 11w ago | 6-K | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | Press Release | $14.27 | awaiting T+60 | awaiting T+60 | $13.51 (−5.33%) |
Aug 10, 2026 11w ago | 6-K | $13.60 | awaiting T+60 | awaiting T+60 | $13.51 (−0.66%) |
Jul 21, 2026 14w ago | 6-K | $13.32 $13.74 | ▲ +3.15% | ▼ −0.82% | $13.51 (+1.43%) |
Jul 15, 2026 14w ago | 6-K | $12.46 $14.00 | ▲ +12.36% | ▲ +9.83% | $13.51 (+8.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers